FINWIRES · TerminalLIVE
FINWIRES

キンロス・ゴールドは、第1四半期決算発表後、スティフェル・カナダの投資判断で「買い」に据え置かれ、目標株価は65.00カナダドルに維持された。

By

-- スティフェル・カナダは木曜日、キンロス・ゴールド(K.TO、KGC)の第1四半期決算発表を受け、同社の株式に対する買い推奨と目標株価65.00カナダドルを維持した。 「キンロスは、2026年第1四半期の調整後EPSが0.71ドル(当社の予想は0.69ドル、コンセンサスは0.72ドル)で、帰属GEO生産量は492.6Koz(当社の予想は489.8Koz、コンセンサスは481.8Koz)でした。帰属売上原価は1,380ドル/GEO、AISCは1,732ドル/GEOで、いずれも2026年度ガイダンス範囲(それぞれ1,360ドル±5%、1,730ドル±5%)の範囲内でした。調整後2026年第1四半期EPSには9,100万ドルの源泉徴収税が計上されており、そのうち6,500万ドルはモーリタニアのキャッシュフローの本国送金に関連して将来の四半期に支払われる税金です。記録的な2026年第1四半期の帰属FCFは8億3,750万ドルで、FCF/GEO(運転資本控除後)は金価格は1オンスあたり2,656ドル(前四半期比+1,034ドル、+63.8%)で、金価格は1オンスあたり+722ドル、+17.4%でした。キンロスは2026年第1四半期に2億5,010万ドル相当の自社株買いを実施し(4月には5,000万ドル)、フリーキャッシュフローの40%を株主還元目標とする方針を再確認しました。当社は、2026年の自社株買い額を約13億ドル(2025年は6億ドル)、発行済株式総数の3.4%(2025年は2.5%)と推定しています。2026年第1四半期の総流動資産は39億ドルで、うち現金は22億ドル(前四半期比+4億4,300万ドル)でした」と、アナリストのラルフ・プロフィティ氏は述べています。 (は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください:https://www..com/contact-us

Price: $40.93, Change: $+0.07, Percent Change: +0.17%

Related Articles

Research

Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.

$AMGN
Research

Research Alert: Illumina: Sequencing Sales Growth Supports Q1 Eps Beat, Guidance Increased

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Illumina reported Q1 2026 adjusted EPS of $1.15, up 18.6% Y/Y and beating the $1.05 consensus estimate, while revenue grew 4.8% to $1.091B. Operating leverage was evident, with adjusted operating margin expanding 150 bps Y/Y to 21.9% due to consumables growth of 4.3% to $726M and instruments up 8.3% to $118M. The instrument growth suggests continued NovaSeq X adoption momentum, while rest-of-world organic revenue growth of 3.5% indicates healthy demand outside of China (declined 29% organically). ILMN raised full-year guidance, increasing revenue expectations by $20M at the midpoint to $4.52B-4.62B and adjusted EPS to $5.15-5.30 from $5.05-5.20. We view the recently-completed SomaLogic acquisition positively, as it expands ILMN's addressable market into proteomics and strengthens its multiomics portfolio. Strong cash generation was also present, with operating cash flow up 20.4% to $289M, supporting the newly-authorized $1.5B share repurchase program.

$ILMN
Research

Research Alert: CFRA Lowers Opinion On Shares Of Bxp, Inc. From Hold To Sell

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We decrease our target by $10 to $51, 7.5x our 2026 FFO estimate as occupancy headwinds remain with large capex increases now planned to improve leasing. We lower our 2026 FFO forecast by $0.05 to $6.82 and 2027's by $0.22 to $7.03. BXP's most concerning headline in Q1 was the increase in capex planned to drive 2026 leasing going from $220M-$250M all the way up to $400M. In our view, this indicates that vacant properties likely need significant concessions to tenants or redevelopment spending from BXP to improve structurally impaired occupancy. Management believes BXP stock is attractive now but unable to repurchase due to high leverage, which we consider concerning given the weakness in leasing and negative re-leasing spreads. Leasing improved in Q1 in San Francisco, but remains negative in Boston/New York (BXP's largest CBD markets). We expect further disposition activity ($400M more this year) and share issuance in 2026, with the goal of reducing leverage.

$BXP